Stock comparison
Catalyst Pharmaceuticals
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CPRX
Catalyst Pharmaceuticals
Market cap
$3.83B
Sector
Healthcare
RMD
ResMed
Market cap
$30.31B
Sector
Healthcare
Overall winner
Catalyst Pharmaceuticals CPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CPRX | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 69C | 72B | RMD |
| Benjamin Graham | 75B | 75B | Tie |
| Philip Fisher | 87C | 75B | CPRX |
| Peter Lynch | 65B | 58C | CPRX |
| Joel Greenblatt | 42D | 47D | RMD |
| Charlie Munger | 78B | 69B | CPRX |
| Terry Smith | 78B | 73B | CPRX |
Side-by-side metrics
| Metric | CPRX | RMD |
|---|---|---|
| Market cap | $3.83B | $30.31B |
| P/E (TTM) | 17.3x | 19.6x |
| EV/EBIT | 11.9x | 17.1x |
| ROIC (TTM) | 19.67% | 19.63% |
| Gross margin | 82.32% | 61.69% |
| Net margin | 37.08% | 27.44% |
| Revenue CAGR 5y | 43.0% | 12.64% |
| EPS CAGR 5y | 46.49% | 30.73% |
| Debt / Equity | 0.0x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CPRX leads on
- Debt / Equity0.0xvs 0.1x+98%
- Revenue CAGR 5y43.0%vs 12.64%+71%
- EPS CAGR 5y46.49%vs 30.73%+34%
- EV/EBIT11.9xvs 17.1x+30%
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.31Bvs $3.83B+87%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.